5-Day versus 10-Day Course of Fluoroquinolones in Outpatient Males with a Urinary Tract Infection (UTI)

References

1. 1.↵
   1. Gaspari R,
   2. Bosker G

   . Urinary tract infection: risk stratification, clinical evaluation, and evidence-based antibiotic therapy. Primary Care Consensus Reports, January 15, 2003. Atlanta, GA: American Health Consultants; 2003.
2. 2.↵
   1. Hooton TM

   . Uncomplicated urinary tract infection. N Engl J Med 2012;366:1028–37.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   1. Lipskv BA

   . Urinary tract infections in men. Epidemiology, pathophysiology, diagnosis and treatment. Ann Intern Med 1989;110:138–50.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Drekonja DM,
   2. Rector TS,
   3. Cutting A,
   4. Johnson JR

   . Urinary tract infection in male veterans. JAMA Intern Med 2013;173:62–8.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Sanchez GV,
   2. Master RN,
   3. Karlowsky JA,
   4. Bordon JM

   . In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010. Antimicrob Agents Chemother 2012;56:2181–3.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Meyer E,
   2. Gastmeiera P,
   3. Dejab M,
   4. Schwaba F

   . Antibiotic consumption and resistance: data from Europe and Germany. Int J Med Microbiol 2013;303:388–95.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Khawcharoenporn T,
   2. Vasoo S,
   3. Ward E,
   4. Singh K

   . High rates of quinolone resistance among urinary tract infections in the ED. Am J Emerg Med 2012;30:68–74.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Gottesman BS,
   2. Carmeli Y,
   3. Shitrit P,
   4. Chowers M

   . Impact of quinolone restriction on resistance patterns of Escherichia coli isolated from urine by culture in a community setting. Clin Infect Dis 2009;49:869–75.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Zhanel GG,
   2. Hisanaga TL,
   3. Laing NM,
   4. et al

   . Antibiotic resistance in outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents 2005;26:380–8.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    1. Peterson J,
    2. Kaul S,
    3. Khashab M,
    4. Fisher AC,
    5. Kahn JB

    . A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology 2008;71:17–22.

    OpenUrlCrossRefPubMedWeb of Science
11. 11.↵
    1. Dalhoff A

    . Global fluoroquinolone resistance epidemiology and implications for clinical use. Interdiscip Perspect Infect Dis 2012;2012:976273.

    OpenUrlCrossRefPubMed
12. 12.↵
    U.S. Food and Drug Administration. FDA drug safety communication. FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. May 12, 2016. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM500591.pdf. Accessed May 16, 2016.
13. 13.↵
    1. Liu HH

    . Safety profile of the fluoroquinolones: focus on levofloxacin. Drug Saf 2010;33:353–69.

    OpenUrlCrossRefPubMedWeb of Science
14. 14.↵
    1. Levy SB

    . Factors impacting on the problem of antibiotic resistance. J Antimicrob Chemother 2002;49:25–30.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Dellit TH,
    2. Owens RC,
    3. McGowan JE,
    4. et al

    . Guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007;44:159–77.

    OpenUrlFREE Full Text